Lupin's Goa facility may face regulatory action, says USFDA

The USFDA has stated that it may withhold approval of any pending applications or supplements in which this facility is listed," it added.

from Healthcare/Biotech-Industry-Economic Times http://bit.ly/2Qz6SEx
via IFTTT